Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

PacBio Enters Carrier Screening Market With PureTarget Expansion

by Zacks Equity Research

PACB expands its PureTarget portfolio, streamlining carrier screening with HiFi sequencing to meet rising global demand.

Zacks Equity Research

QuidelOrtho Expands Portfolio With the Launch of FDA-Approved Test

by Zacks Equity Research

QDEL boosts its respiratory testing lineup with the FDA-cleared QUICKVUE Influenza + SARS Test for professional use.

Zacks Equity Research

DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute

by Zacks Equity Research

Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.

Sridatri Sarkar headshot

Tempus AI Enhances Cancer Research Tools With FDA-Cleared xR IVD

by Sridatri Sarkar

TEM secures FDA clearance for its xR IVD device, advancing RNA-based cancer research and precision medicine tools.

Zacks Equity Research

INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream

by Zacks Equity Research

Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.

Zacks Equity Research

QGEN Stock Gains From CE-IVDR Certification for QIAstat-Dx Portfolio

by Zacks Equity Research

QIAGEN secures CE-IVDR certification for its full QIAstat-Dx portfolio, boosting its diagnostics arm and lifting shares.

Moumi Mondal headshot

Hologic's 2025 Outlook Improves on Strong Q3, Easing Tariff Headwinds

by Moumi Mondal

HOLX lifts its 2025 revenue and EPS outlook on Q3 strength, tariff relief, and growth across Breast Health and GYN Surgical.

Zacks Equity Research

QIAGEN Stock May Benefit From the US Clearance of QIAstat-Dx Rise

by Zacks Equity Research

QGEN announces the launch of FDA-cleared QIAstat-Dx Rise, which may boost U.S. diagnostic access and testing capacity worldwide.

Moumi Mondal headshot

The Role of M&A in Hologic's Growth Story: Are More Deals in Sight?

by Moumi Mondal

HOLX fuels growth with targeted M&A across Diagnostics, Breast Health, and GYN Surgical, backed by a strong balance sheet.

Zacks Equity Research

INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?

by Zacks Equity Research

Incyte hits a fresh 52-week high on strong Jakafi and Opzelura sales, pipeline wins and upbeat investor sentiment.